Results 231 to 240 of about 13,011 (272)

Fe(deferasirox)2: An Iron(III)-Based Magnetic Resonance Imaging T1 Contrast Agent Endowed with Remarkable Molecular and Functional Characteristics.

Journal of the American Chemical Society, 2021
The search for alternatives to Gd-containing magnetic resonance imaging (MRI) contrast agents addresses the field of Fe(III)-bearing species with the expectation that the use of an essential metal ion may avoid the issues raised by the exogenous Gd ...
L. Palagi, Enza Di Gregorio, Diana Costanzo, R. Stefania, Camilla Cavallotti, Martina Capozza, S. Aime, E. Gianolio   +7 more
semanticscholar   +1 more source

Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study

British Journal of Haematology, 2022
Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The ‘RUX‐IOL’ study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX for IOL to assess ...
E. Elli, A. Di Veroli, D. Bartoletti, A. Iurlo, I. Carmosino, G. Benevolo, E. Abruzzese, M. Bonifacio, M. Bergamaschi, N. Polverelli, M. Caramella, D. Cilloni, M. Tiribelli, N. Pugliese, G. Caocci, E. Crisà, R. Porrini, U. Markovic, Rossella Renso, G. Auteri, D. Cattaneo, M. Trawinska, L. Scaffidi, L. Biale, C. Bucelli, M. Breccia, C. Gambacorti-Passerini, G. Palumbo, R. Latagliata, F. Palandri   +29 more
semanticscholar   +1 more source

Deferasirox

American Journal of Health-System Pharmacy, 2007
The pharmacology, clinical efficacy, adverse effects and toxicities, and the economic issues that should be considered in using deferasirox are reviewed.Iron overload is a complication of the chronic blood transfusions used to treat several hematologic disorders. To date, management of transfusional iron overload has consisted of chelation therapy with
openaire   +2 more sources

Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study

Journal of pharmacy and practice, 2022
Background: Deferasirox has proved good efficacy and acceptable safety for the management of thalassaemia patients. However, some patients are unresponsive or intolerant to once-daily administration of deferasirox even at a high dose.
G. M. Panachiyil, T. Babu, J. Sebastian, M. Ravi   +3 more
semanticscholar   +1 more source

Cardiac effects of deferasirox in transfusion‐dependent patients with myelodysplastic syndromes: TELESTO study

British Journal of Haematology
Iron overload from repeated transfusions has a negative impact on cardiac function, and iron chelation therapy may help prevent cardiac dysfunction in transfusion‐dependent patients with myelodysplastic syndromes (MDS).
M. Sarocchi, Junmin Li, Xiao Li, Depei Wu, E. M. Montaño Figueroa, Maria Guadalupe Rodriguez, M. Hou, C. Finelli, Hongxia Shi, Zhijian Xiao, E. Oliva, Liana Gercheva Kyuchukova, Mark Drummond, A. Symeonidis, Eric J Velazquez, G. Rivoli, Miguel Izquierdo, Yogita Kolekar, P. Spallarossa, E. Angelucci   +19 more
semanticscholar   +1 more source

Deferasirox

Reactions Weekly, 2022
  +6 more sources

Deferasirox: An Update

Hemoglobin, 2009
Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). Pivotal preregistration studies established the relationship between dose, iron excretion, and tolerability using changes in liver iron concentration (LIC) to ...
openaire   +2 more sources

Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota.

Life Science, 2022
Yi Wu, Lei Ran, Yue Yang, Xianling Gao, Man Peng, Sida Liu, Le Sun, J. Wan, Yu Wang, Kun Yang, Mingxiao Yin, W. Chunyu   +11 more
semanticscholar   +1 more source

An extensive experimental and DFT studies on highly selective detection of nitrobenzene through deferasirox based new fluorescent sensor.

Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy, 2023
Muhammad Zahid Ullah, Sohail Anjum Shahzad, M. Assiri, Hasher Irshad, Sanwa Rafique, Syed Ahmed Shakir, Amara Mumtaz   +6 more
semanticscholar   +1 more source

Theoretical and experimental studies on mechanochromic triphenylamine based fluorescent "ON-OFF-ON" sensor for sequential detection of Fe3+ and deferasirox.

Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy, 2023
Abdullah Y. A. Alzahrani, Khanzadi Omama Khan, Sanwa Rafique, Hasher Irshad, Khadija, Asad Muhammad Khan, S. Shahzad   +6 more
semanticscholar   +1 more source